Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fulgent Pharma LLC.
Gilead Sciences
University of Pittsburgh
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
Wake Forest University Health Sciences
University of Michigan Rogel Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Iovance Biotherapeutics, Inc.
University of Chicago
Medical University of Vienna
University of Chicago
Thomas Jefferson University
Replimune Inc.
Ohio State University Comprehensive Cancer Center
Latin American Cooperative Oncology Group
The First Affiliated Hospital with Nanjing Medical University
University of Chicago
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lyvgen Biopharma Holdings Limited
Centre Leon Berard
Sun Yat-sen University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Ohio State University Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
First Affiliated Hospital of Zhejiang University
Jonsson Comprehensive Cancer Center
Novartis
Fox Chase Cancer Center
Dana-Farber Cancer Institute
University of Arkansas
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Oncolytics Biotech
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
M.D. Anderson Cancer Center
National Cancer Institute (NCI)